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Abstract 41 
Background 42 
The ongoing Ebola outbreak led to accelerated efforts to test vaccine candidates. Following a 43 
request by WHO, a Phase I/IIa clinical trial of the monovalent Ebola (Zaire) vaccine ChAd3-44 
EBO-Z was conducted in healthy adults in Lausanne, Switzerland. 45 
 46 
Methods 47 
This randomized, double-blind, placebo-controlled, dose-finding trial assessed safety and 48 
immunogenicity of ChAd3-EBO-Z vaccine. All volunteers were assigned to three arms, 5 49 
x10
10
 vp dose,  2.5x10
10
 vp dose or placebo (ratio 2:2:1). However, 18 volunteers at potential 50 
risk of exposure to Ebola virus while deployed in epidemic areas were randomized only into 51 
the two vaccine arms (5x10
10 
and 2.5x10
10
). The latter, not blinded, were not included in the 52 
safety analysis for comparison between the vaccine doses and placebo but were pooled with 53 
the non-deployed group to compare immunogenicity between the different arms.  Safety and 54 
immunogenicity were assessed up to 6 months post vaccination.  55 
 56 
Results 57 
120 subjects were recruited. No vaccine-related SAE was observed. Local AEs were observed 58 
in 30/40(75%) of 5x10
10
, 33/42(78.6%) of 2.5x10
10
 and 5/20 (25%) of placebos. Headache 59 
was the most frequent systemic AE [26/40 (65%), 29/42 (69%) and 6/20 (30%) respectively] 60 
followed by fatigue/malaise [26/40 (65%), 27/42 (64%), 6/20 (30%)]. Fever occurred during 61 
the 24h post injection in 30% of vaccinees. Geometric mean concentrations (GMC) of IgG 62 
antibodies against Ebola glycoprotein peaked on day 28 (51µg/ml [95% CI 41.1-63.3] in 63 
5x10
10
 arm, 44.9µg/ml [25.8-56.3] in 2.5x10
10
 arm and 5.2µg/ml [3.5-7.6] in placebos) with 64 
respective response rates of 96% [85.7-99.5], 96% [86.5-99.5] and 5% [0.1-24.9]. GMC 65 
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decreased to 25.5µg/ml, 22.1µg/ml and 3.2µg/ml on day 180.With regards to cell mediated 66 
immunity, 57.1% and 60.8% of vaccinees from the 5x10
10
 and the 2.5x10
10
 arms developed 67 
GP specific CD4+ responses  and 67.3% and 68.6% GP specific CD8+ responses respectively. 68 
 69 
 70 
Conclusion 71 
ChAd3-EBO-Z was safe and well tolerated, although mild to moderate systemic AEs were 72 
frequent. A single dose was immunogenic in almost all vaccinees. Antibody responses were 73 
still significantly present at 6 months. There was no significant difference between doses for 74 
safety and immunogenicity outcomes.  75 
 76 
Funding: Swiss Secretariat for Education, Research and Innovation as Swiss partner of the 77 
European Union’s Horizon 2020 Research and Innovation Programme project EbolaVac. 78 
 79 
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Introduction 81 
Ebola virus causes a severe, often fatal illness that has occurred in a number of outbreaks 82 
since it was first reported in 1976. The largest recorded outbreak of Ebola virus disease 83 
(EVD) is ongoing, and there have been more than 28,000 reported cases and more than 84 
11,000 deaths in 3 countries in West Africa by September 2015(1). The World Health 85 
Organization (WHO) has declared the current outbreak as an international public health 86 
emergency.Thanks to large multilateral public health interventions, the case incidence 87 
dropped down to less than 10 cases per week since end of July 2015, but there is as yet no 88 
approved treatment or vaccine available against EVD. 89 
Current efforts to develop a vaccine are focused on the viral glycoprotein (GP) encoded by the 90 
virus. The most advanced vaccine candidates tested so far are based on the GP from the Zaire 91 
ebolavirus species (responsible for the current outbreak of EVD), and/or the Sudan species. 92 
Candidates in which viral GP is expressed in either chimpanzee adenovirus (ChAd), Human 93 
Adenovirus (Ad5) or vesicular stomatitis (VSV) vector have shown promise in non-human 94 
primate models of EVD and in initial clinical trials(2–7). Moreover, preliminary results of a 95 
phase III clinical trial using the rVSV-vectored vaccine showed encouraging efficacy results 96 
in Guinea(8,9). 97 
The rationale for the development of this vaccine is based on previous human experience with 98 
other investigational filovirus vaccines and the development of non-human adenovirus vectors 99 
with low seroprevalence in humans(3,10–14). 100 
The present Phase I/IIa study was directed at assessing safety and immunogenicity of the 101 
monovalent ChAd3-EBO-Z vaccine construct. It was preceded by Ledgerwood et al. and 102 
Rampling et al. who reported on phase I clinical trials of the bivalent (ChAd3-EBO) and 103 
monovalent (ChAd3-EBO-Z) vaccines encoding wild type GP from Zaire and Sudan species 104 
of Ebolavirus(4)
 
or Zaire only(15).
 
It builds on and extends the clinical development plan for 105 
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a ChAd3-vectored vaccine encoding Ebola glycoproteins that has been developed by NIH in 106 
collaboration with GSK/Okairos, WHO and University of Oxford. It complements the plan in 107 
several key areas: first, the present study, is the only one, among the ChAd3 vectored Ebola 108 
vaccine studies, that includes a placebo arm, which allows a precise assessment of the vaccine 109 
reactogenicity; second with its large sample size it considerably increases the data already 110 
collected in previous studies and allows a better evaluation of safety and two dosage 111 
responses, increasing the likelihood of identifying an optimal dose that balances both 112 
immunogenicity and reactogenicity; third it is the first report among all Ebola vaccine clinical 113 
trials that provides safety and immunogenicity data at 6 months. Altogether, these results have 114 
greatly assisted in decision-making for the initiation of further phase IIb and III trials in 115 
Africa with a single injection intended for preventing and controlling outbreaks. 116 
 117 
Methods 118 
Study design and participants 119 
This is a randomized, double-blind, placebo-controlled, dose finding safety and 120 
immunogenicity Phase I/IIa trial conducted at the Centre Hospitalier Universitaire Vaudois 121 
(CHUV), Lausanne, Switzerland. The study was reviewed and approved by the local ethics 122 
review board (CER-VD), by the WHO Research Ethics Review Committee (WHO ERC) and 123 
by the Swiss regulatory authorities (Swissmedic). All participants were recruited in the 124 
regions of Lausanne using advertisements in the hospital and university halls. Since the study 125 
was largely published in the press, many people contacted the team directly to ask for their 126 
participation. All subjects provided written informed consent before enrolment.  127 
 128 
Inclusion and exclusion criteria summary 129 
Included subjects had to be healthy, aged 18 to 65 years and to practice continuous 130 
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contraception during the whole study. The main exclusion criteria were: prior participation to 131 
an investigational Ebola or Marburg vaccine or a chimpanzee adenovirus vectored vaccine 132 
trial, receipt of any other live or killed vaccine within 28 or 14 days respectively, before the 133 
trial, any immunodeficiency state or any acute or chronic disease not well controlled which 134 
could increase the risk for the volunteer to have a serious adverse event, or impair 135 
interpretation of the data (complete Inclusion and Exclusion criteria are listed in the 136 
Supplemental Material). 137 
 138 
Vaccine 139 
The recombinant Chimpanzee Adenovirus type-3 vectored Ebola Zaire vaccine (ChAd3-140 
EBO-Z) consists of a recombinant replication-deficient Adenovirus chimpanzee serotype 3 141 
(ChAd3) vector expressing wild-type (WT) Ebola glycoprotein (GP) from the Zaire Mayinga 142 
strain. Details about the composition of vaccine and diluent are given in the Supplementary 143 
material.  144 
 145 
Procedures 146 
For all volunteers, the intra-muscular injection was performed under double-blind conditions. 147 
Local and systemic adverse events (AEs) were assessed 1 hour post-injection and at follow-up 148 
visits on D1, D7, D14, and D28. In addition, volunteers recorded AEs in a daily notification 149 
sheet for the first week. Solicited AEs were adverse events which occurred at any time from 150 
injection up until D7, and included both local (pain, erythema and swelling at injection site, 151 
plus axillary lymph node enlargement) and systemic AEs (fever, fatigue/malaise, musculo-152 
articular pain, headache, chills, and nausea). Unsolicited AEs were all other AEs not listed 153 
above and all AEs which occurred after the 7-day follow-up and up to D28. Grading of AEs 154 
for severity and assignment of causal relationship of unsolicited AEs (Supplementary 155 
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material) was assessed by clinicians in charge of monitoring the volunteers during the whole 156 
study according to pre-defined criteria in the study protocol. 157 
Safety biological monitoring was performed on blood samples taken on D0, D1, D7, D14, and 158 
D28 post-injection, and included a full blood count, electrolytes, liver and renal function tests, 159 
C-reactive protein (CRP) and activated partial thromboplastin time (aPTT). This assay was 160 
performed since an asymptomatic prolongation of aPTT had been observed in the 2 weeks 161 
following vaccination in previous adenovirus vaccine trials. This was due to the induction of a 162 
non-specific antiphospholipid antibody (APA) and not due to coagulopathy. This effect is 163 
actually an artifact of the aPTT test as this test measures the clotting cascade and the assay 164 
requires the presence of phospholipid as a reagent(3,15). 165 
 At 3 months post injection, a follow-up took place via phone call or email, to record the 166 
occurrence of serious adverse events (SAEs) or relevant AEs possibly related to injection. At 167 
6 months post injection, a last follow-up visit was performed to collect SAEs or relevant 168 
unsolicited AEs as well as laboratory samples.  169 
 170 
Immunogenicity  171 
See methods for antibody measurement and cell mediated immunity evaluation in the 172 
Supplemental Material. 173 
 174 
Sample size  175 
The sample size of 100 vaccinated was calculated to achieve a total of 250 vaccinated 176 
subjects taking into account all three concurrent Phase I trials of the ChAd3-EBO-Z vaccine 177 
(Lausanne, Oxford and Mali).  This sample size allowed having reliable data on the incidence 178 
of frequent adverse events. 
 
179 
 180 
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 181 
Randomisation 182 
Volunteers were randomised in three arms, i) single dose of the Ebola Zaire vaccine ChAd3-183 
EBO-Z 5x10
10
 viral particles (vp),  ii) single dose of ChAd3-EBO-Z 2.5x10
10
 vp or iii)  single 184 
dose of placebo (diluent only) in a ratio of 2:2:1. The rationale to choose the two doses with 185 
only a two-fold difference was based on previous safety experience in clinical trials with 186 
ChAd vectors (16).
 
187 
Since 100% of the non-human primates were protected one month post vaccination, there was 188 
a clear signal that this vaccine could be effective in humans. Therefore, deployed volunteers 189 
from non-epidemic to epidemic areas could be the first beneficiaries of the vaccine, reason 190 
why World Health Organization requested not to include a placebo arm among those 191 
volunteers. They were thus randomised in two vaccine arms (5x10
10 
and 2.5x10
10
) only, 192 
without placebo (Figure 1).  193 
Subjects were randomised following two randomisation runs resulting in two lists, one for the 194 
possibly deployed volunteers and one for the non deployed ones. The randomisation lists were 195 
computer-generated and kept confidential in the central pharmacy at CHUV.  196 
 197 
 198 
Data analysis 199 
Only the non-deployed group results were used to compare safety between the 5x10
10
, 200 
2.5x10
10
 and control arms while all deployed and non-deployed group results were pooled to 201 
compare immunogenicity between the different arms as laboratory team performing antibody 202 
or cellular responses analyses was blinded to the group assignment. Indeed, blinding is 203 
essential for accurate safety and laboratory assessment, in this trial safety evaluation for 204 
deployed volunteers was not blinded as mentioned previously, therefore the two groups were 205 
not merged for safety analysis.  Also, too few of the volunteers had gone to epidemic area 206 
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after vaccination to expect potential immunological boost after hypothetical exposure. Anti-207 
Ebola-GP IgG concentrations were described as geometric mean concentration (GMC) with 208 
95% confidence intervals. Allocation arms were compared using the Fisher’s exact test for 209 
safety and Mann Whitney test for immunogenicity. The lower dose was compared with the 210 
higher dose, and the two doses were pooled and named “vaccinated” for comparison with 211 
placebo.  212 
For each subject, a positive antibody response was defined as a significant increase in post-213 
vaccination titer from baseline (t-test assuming non-equal variance), using the anti-214 
glycoprotein antibody titers assessed by enzyme-linked immunosorbent assay (ELISA) done 215 
in the Vaccine Research Center (VRC) (National Institute of Health, US)(11). Friedman or 216 
Kruskal-Wallis with Dunn’s post tests were performed for comparison of magnitude of T-cell 217 
responses to pre-vaccination or between groups using GraphPrism software v6.07. 218 
 219 
Data Safety Monitoring Board  220 
A Data Safety Monitoring Board (DSMB) was established prior to the trial initiation 221 
including two independent clinicians and one epidemiologist. The DSMB reviewed the safety 222 
data of days 0 to 7 of the 20 first subjects vaccinated to ensure that holding rules were not 223 
met.  224 
 225 
Role of the funding source 226 
The funder of the study had no role in study design, data collection, data analysis, data 227 
interpretation, or writing of the report. The corresponding author had full access to all the data 228 
in the study and shared the final responsibility with the principal investigator of the trial for 229 
the decision to submit for publication.  230 
 231 
 232 
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Results 233 
The WHO request to conduct the trial came on September 1
st
 2014. Screening of volunteers 234 
started on October 24
th
 2014. Vaccinations were administered from October 31
st
 to December 235 
12
th
 2014. The 6-month follow-up ended on June 22
nd
 2015.  236 
 237 
Study population 238 
Demographic data of the included participants are detailed in Table 1. All 120 volunteers 239 
completed the 6 visits post-injection except two deployed volunteers who missed one visit 240 
each (D14 and D28).  241 
 242 
Safety 243 
No vaccine-related SAE was observed. Most of the AEs reported were mild and self-limiting, 244 
appearing during the first 24h after injection and lasting <48 hours. Seven grade 3 AEs 245 
(described below)  were observed and all resolved within 3 days with no residual effect. 246 
Proportions of volunteers with AEs up to D28 in the vaccine and placebo arms are shown in 247 
Figure 2; absolute numbers and differences between arms are detailed in Table 2. Only the 248 
placebo-controlled results from the 102 non-deployed volunteers are shown in text below.  249 
The most frequent solicited local AE was pain (91% grade 1) with significant difference 250 
between vaccine and placebo arms (77% vs 25% respectively, p<0.01), but without difference 251 
between vaccine dose arms (75% 5x10
10
, 79% 2.5x10
10
, p=0.79). At least one solicited 252 
systemic AE was reported in 87% of subjects in the vaccine arms (93% 5x10
10 
and
 
81% 253 
2.5x10
10
) and 50% of placebos (p<0.01). The most frequent solicited systemic AEs were 254 
headache (65% 5x10
10
, 69% 2.5x10
10
 and 30% placebo) and fatigue/malaise (65% 5x10
10
,
 
255 
64% 2.5x10
10
 and 30% placebo). Musculo-articular pains were also frequently observed (57% 256 
5x10
10
,
 
43% 2.5x10
10
 and 25% placebo). Most solicited AEs were mild and resolved within 257 
12 
 
24 hours after injection. 30% of non-deployed vaccinees developed fever, versus 5% of 258 
placebos, with no significant difference between the dose arms (32% 5x10
10 
and 29% 259 
2.5x10
10
). However, as shown in Figure 1S, the highest vaccine-related temperatures were 260 
seen in the 5x10
10
 arm. 261 
One relevant unsolicited AE possibly related to the vaccine was an episode of macroscopic 262 
haematuria associated with alguria and mild left costovertebral angle tenderness at percussion 263 
that occurred within 24 hours after injection (2.5x10
10
). The investigations (urinary sediment 264 
and culture, renal US, blood count, coagulation assays) were normal and the episode 265 
spontaneously resolved 48 hours after injection. Since no biological cause was found for this 266 
episode and since the volunteer never experienced any similar episode before, the AE was 267 
considered possibly related to the vaccine. A second relevant unsolicited AE possibly related 268 
to the vaccine (5x10
10
) was a herpetiform dermatitis that occurred at day 15 post injection and 269 
lasted for 2 weeks. Located in the L2 dermatoma, it was clinically diagnosed as shingles 270 
although not confirmed by PCR. 271 
None of the laboratory abnormal values were clinically significant ( Tables 1S and 2S and 272 
Figure 2S). At D1, 60 grade 1 (<1.5-0.8 G/l) (53% 5x10
10
, 55% 2.5x10
10
 and 30% placebo) 273 
and 4 grade 2 transient lymphopenias (<0.8-0.5 G/l) (2% 5x10
10
, 6% 2.5x10
10
 and 0% 274 
placebo) and 3 transient grade 1 thrombocytopenias (platelets count <150-75G/l) (4% 5x10
10 
275 
and 2% 2.5x10
10
) were observed. During the one-month follow-up, 8 transient grade 1 276 
anaemias (Hb <117-100g/l) (2% 5x10
10
, 14% 2.5x10
10
 and 0% placebo) and 14 transient 277 
neutropenias were observed (grade 1 (< 1.8-1.5 G/l): 8% 5x10
10
, 6% 2.5x10
10
  and 5% 278 
placebo,  grade 2 (<1.5-1 G/l): 2% 5x10
10
, 6% 2.5x10
10
  and 0% placebo and 2 grade 3 (<1 279 
G/l): 2% 5x10
10
, 0% 2.5x10
10
 and 5% placebo). Two cases of asymptomatic grade 1 280 
prolonged aPTT were observed at D14 (5x10
10
). One of our two cases of prolonged aPTT had 281 
resolved at the following visit (D28) and thus did not go under further investigation. 282 
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Investigation of the other one showed no coagulopathy. The antiphospholipid screening was 283 
positive for a lupus anticoagulant and doubtful for an anticardiolipin IgM. The aPTT and 284 
anticardiolipin had resolved by 3 months. The lupus anticoagulant resolved by 9 months. No 285 
associated clinical sign of hypercoagulability was present.  286 
Among the grade 3 AEs, one was an unsolicited local AE, 4 were solicited systemic AEs, and 287 
two were laboratory AEs. The one local grade 3 AE was an erythema at injection site of 11 cm 288 
of diameter with presence of redness and warmness but no pain, which appeared at day 9 and 289 
lasted for less than 24 hours, in the 5x10
10
 arm. Among the 4 solicited systemic grade 3 AEs, 290 
two were sudden and strong headaches that appeared during the 24 hours following the 291 
injection and resolved in less than 2 hours with paracetamol. The other two were fevers with 292 
temperatures exceeding 39°C, one during the night post injection (5x10
10
) and lasting less 293 
than 24 hours, and the other one appeared at day 4 post injection (2.5x10
10
) but was 294 
associated with a streptococcus angina and therefore not related to the vaccine. Two grade 3 295 
neutropenias were observed, the first, at D1 (5x10
10
) and the second, at D14 (placebo). None 296 
were associated with symptom or clinical sign and both were resolved at the following visit 3 297 
days later. 298 
 At the 3-month follow-up all volunteers except one were reached by phone or email to assess 299 
safety. Three mild to moderate AEs were possibly related to the injection. One was a second 300 
episode of an axillary lymph node enlargement, at day 63 post injection (5x10
10
), and lasted 2 301 
days (first episode previously described at D1 and lasted 2 days). The two other AEs were a 302 
mild fatigue at day 34 and lasted one week (5x10
10
), and a moderate fatigue with several 303 
episodes of frontal headache at day 34 and lasted for approximatively 3 weeks (2.5x10
10
). 304 
Upon last visit at 6 month, only one AE was reported as possibly related to the vaccine. The 305 
volunteer reported mild arthralgia in the distal interphalangeal joints of the 5th fingers on both 306 
hands of one month duration. Neither swelling nor warmth was observed. Mobility was 307 
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normal but a light red macula of 2-3 millimetres was observed on the dorsal face of each joint. 308 
This volunteer had received the placebo and was sent to a specialized consultation for further 309 
investigations. 310 
From D28 to D180, 3 SAE were reported, none related to the injection, all due to trauma, 311 
namely, an elective hospitalisation for a dislocated shoulder surgery (placebo), an emergency 312 
hospitalisation and surgery for a broken radius (placebo), and an elective hospitalisation for a 313 
broken anterior cruciate knee ligament surgery (in the 2.5x10
10
 arm) 314 
  315 
Lastly, at the 3-month follow-up visit, a volunteer (2.5x10
10
) reported the pregnancy of his 316 
wife. At this time the pregnancy was in the first trimester. The date of conception was difficult 317 
to determine because this was an unexpected pregnancy under oral contraception, but it was 318 
estimated at 2 weeks after the vaccination of the volunteer. The pregnancy was terminated 3 319 
weeks later because of a trisomy 21 diagnosed by the gynaecologist. There is no biological 320 
plausibility that this diagnosis could be related to the vaccination of the partner. 321 
 322 
Immunogenicity 323 
Ebola GP specific antibody response. 324 
Anti-Ebola GP IgG results are summarised in Figure 3, including all data from deployed and 325 
non-deployed vaccinees. 326 
Antibody response was detected from D14 onwards and peaked at D28 up to a geometric 327 
mean of 51 µg/ml [95%CI: 41.1-63.3] in the 5x10
10
 arm and of 44.9 µg/ml [25.8-56.3]  in the 328 
2.5x10
10
 arm. There was no difference in antibody concentration between the two vaccine 329 
dose arms. The percentage of responders was 96% [85.7-99.5] in the 5x10
10
, 96% [86.5-99.5] 330 
in the 2.5x10
10
 and 5% [0.1-24.9] in the placebo arm (table 3S in Supplementary material). 331 
Antibody response decreased by approximately half from D28 to D180 with GMC of 25.5 332 
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µg/ml [20.6-31.5] in the 5x10
10
 arm and of 22.1 µg/ml [19.3-28.6] in the 2.5x10
10
 arm 6 333 
months post injection. 334 
At D28, geometric means of the VRC titers were 434.7 [min-max 77.7-5576.3] for the 5x10
10
 335 
arm, 467.3 [41.5-4265.3] for the 2.5x10
10
, and 33 [6.9-198] for the placebo one (Figure 3B).  336 
Ebola GP specific T cell response. 337 
Mononuclear cell responses to vaccination were evaluated by IFN-γ ELISPOT on D0, D7, 338 
D14, D28 and D180. Responses already increased at D7 in arm 5x10
10
, to peak similarly at 339 
D14 with a significant median response of 177 and 180 SFU / million PBMC in the arms 340 
5x10
10 
and 2.5x10
10
. Although still significantly higher than at D0 (within group analysis 341 
p=0.001, Friedman test), responses at D180 declined in the majority of the subjects and were 342 
not significantly different from placebo (Dunn’s post tests p>0.05) (Figure 3S). Furthermore, 343 
T cell specific response was measured by flow cytometry at D0, D14 and D28 and was 344 
expressed as frequencies of CD4+ and CD8+ producing IFN-γ, IL-2 or TNF-α after 345 
stimulation with GP EBO-Z peptides (Figure 4S). Significant GP specific CD4+ and CD8+ 346 
responses were obtained from D14 in vaccinated arms without significant difference between 347 
doses. Considering positive responses for at least one of the 3 cytokines, 57.1% and 60.8% of 348 
vaccinees from the 5x10
10
 and the 2.5x10
10
 arms developed GP specific CD4+ responses, and 349 
67.3% and 68.6% GP specific CD8+ responses respectively. The vaccine-specific memory 350 
responses showed the same kinetics and were equally distributed between CD4+ and CD8+ T-351 
cells (Figure 4A). Both memory CD4+ and CD8+ T-cells presented poly- and mono-352 
functional phenotypes (Figures 4B and 4C). The CD8+ response consisted mainly of IFN-γ 353 
producing cells among which the IFN-γ TNF-α coproducing subsets represented 40% of the 354 
response. 355 
ChAd3 neutralizing antibodies 356 
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ChAd3 neutralizing antibodies were measured in all volunteers at D0 and D28 (Figure 5S, 357 
panel A). Interestingly, the level of neutralizing antibodies at D0 negatively correlated with 358 
anti-GP Ab responses as well as with CD8
+
 IFN-γ   responses at D28 (Figure 5S, panels B 359 
and C). 360 
 361 
Discussion 362 
This is the largest Phase IIa clinical trial reported to date with an experimental Ebola vaccine, 363 
and the first to report data with a 6-month follow-up. The placebo-controlled design, the large 364 
sample size (120 volunteers) with excellent gender balance, and the extended follow-up 365 
provide reliable safety and immunological data, and allow a valid comparison between doses 366 
and detection of a possible dose-response effect.  367 
 368 
Safety 369 
No vaccine-related SAE was observed during the 6-month follow-up. The ChAd3-EBO-Z 370 
vaccine led to more local and systemic AEs than the diluent alone (placebo). The majority of 371 
AE were mild and all resolved with no sequelae, for most within the first 24 hours. These 372 
results are in line with those observed in other adenovirus-vectored vaccine trials 373 
(3,4,15,17,18). More precisely, the reactogenicity was similar to that observed in previous 374 
phase I trials using Chimpanzee Adenovirus vector and expression proteins from other 375 
pathogens, indicating that adverse events were more likely to be induced by the vector rather 376 
than by the Ebola GP(16–18) .  377 
The placebo arm allowed us to demonstrate that local pain and fatigue/malaise, musculo-378 
articular pain, chills, fever and headache, all components of reactogenicity were due to the 379 
vaccine. Moreover, no unsolicited AE showed any statistical difference between vaccinated 380 
and placebo arms, inferring that larger trials are needed to investigate a potential relationship 381 
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with the vaccine. Local reactogenicity was close to that experienced after routine vaccinations 382 
(such as influenza, hepatitis B, DTPa or MMR vaccinations(19–23) ) with the exception of 383 
pain at injection site which was slightly more frequent (77% of recipients) but almost always 384 
mild and with little erythema or swelling. On the other hand, the incidence of systemic AEs 385 
was markedly higher, especially for headache (65% for 5x10
10
 and 69% for 2.5x10
10
), 386 
musculo-articular pains (57% and 43%) and fever (32% and 29%). Although the safety profile 387 
was roughly similar to  the data published by Rampling et al. ,with headache, fatigue and 388 
malaise being the most frequent AEs (57.5%, 61% and 40% respectively), AEs were more 389 
frequent in our study (headache 67%, fatigue/malaise 65%). They reported only 5% (2 cases) 390 
of ‘objective’ fever whereas we did so for 29%. This difference might be explained by 391 
measurement technique as feverishness was present in 30% of their subjects. Even if more 392 
frequent, AEs were of mild intensity, short-lived and self-limited, which makes them 393 
acceptable in a risk-benefit balance in relation to such a severe disease as Ebola. Moreover, 394 
81% of the fevers induced by the vaccine resolved within 24 hours after injection. This rapid 395 
resolution makes them manageable, even during an outbreak, by preventing confusion with 396 
early onset of a new Ebola case. 397 
Frequencies and intensities of AEs were similar between the two doses, although fevers of 398 
higher temperatures and 4 of 7 grade 3 AEs were observed in the 5x10
10
 arm. The lack of a 399 
significant dose effect observed may be explained by the fact that the two doses differed only 400 
by a factor of two. The slight increase of fever in the 5x10
10
 arm may become clinically 401 
relevant when using the 1x10
11
 dose, the one that is currently deployed in Africa. Indeed, in 402 
the clinical trial of the bivalent ChAd3-EBO (Zaire + Sudan) vaccine, the 2x10
11
 dose was 403 
more reactogenic than the 2x10
10
, with 2/10 vaccinees having fever compared with none with 404 
the lower dose(4). These data may suggest that the 10
11
 dose will be more reactogenic. The 405 
published short-term safety results of the rVSV vaccine trial, the other major promising Ebola 406 
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vaccine, showed a similar early reactogenicity profile. Although no vaccine-related SAEs 407 
have been reported with either vaccine, it is of note that there were cases of arthritis/arthralgia 408 
with maculopapular rash or vesicular dermatitis in some subjects, 2 week post-vaccination 409 
after rVSV. These findings were observed at differing rates in different trials with the highest 410 
reported rate being 22% (11/52) of recipients in Geneva(5) . While ChAd3 vaccine recipients 411 
only complained of transient musculo-articular pain within 3 days post vaccination as part of 412 
general ‘flu-like symptoms’, but without any clinical evidence of arthritis.  413 
Interestingly, in both phase I trials of Ebola vaccine (the rVSV Ebola vaccine (24) and ours), 414 
conducted in Switzerland, a higher frequency of AEs was reported than in other trials with the 415 
same vaccine. This difference is unlikely to be due to specific genetic traits since our 416 
volunteers were of many different origins. This higher frequency of AEs is probably related to 417 
the reporting mode. 418 
 419 
Immunogenicity 420 
A single vaccination with ChAd3-EBO-Z induced antibody responses in 96% of participants, 421 
independently of the dose. The anti-EBO-Z GP titers obtained at D28 (GMT of 434.7 in 422 
5x10
10
 and 467 in 2.5x10
10
) confirmed the responses obtained with 5 and 2.5x10
10
 ChAd3-423 
EBO-Z (GMT of 469 and 402 respectively) in a previous study (15). There was no dose-effect 424 
in our trial, probably due to the fact that the two doses were quite close. The 6-month follow-425 
up showed for the first time that antibody titers were maintained at a level significantly 426 
different when compared to placebo. Interestingly, the presence of ChAd3 neutralizing 427 
antibodies at D0 correlated negatively with the level of anti-GP antibodies at D28 as well as 428 
with the CD8
+ 
IFN-γ T cell responses at D28. This was in line with similar observations in a 429 
previous preliminary report, although here reaching significance in this much larger study 430 
.(4). As far as durability of the T cell response is concerned, the IFN-γ mononuclear cell 431 
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responses by ELISPOT decreased but was still present at month 6 despite lack of significant 432 
difference with placebo at this later time point. Remarkably, the presence of an Ebola specific 433 
CD8+ T-cell response with an IFN-γ TNF-α coproducers component reinforces the potential 434 
for protection of the current vaccine formulation, since these markers are associated with 435 
vaccine-mediated protection in non-human primates(2) . Proportion of IFN-γ TNF-α 436 
coproducers was comparable in this study to a previous study
 
(15) . With comparable dose of 437 
5 and 2.5x10
10
, IFN-polyfunctional CD8 T cells were also found in proportion similar to 438 
our study but appeared to further expend with the highest dose of 2x10
11
(4). The promising 439 
efficacy provided by the VSV-vectored vaccine in Guinea(8) gives hope that other vaccines 440 
based on the Ebola virus GP may be protective. Although correlates of immunity in human 441 
vaccination against EBOV is unknown, it is interesting to see that anti-GP titers observed in 442 
ChAd3-EBO (bivalent) at a dose of 2x10
11 
(4) were equivalent to that obtained with the VSV-443 
vectored vaccine evaluated in the Guinea phase III trial. Available anti-EBO-Z GP ELISA 444 
data indicate that the humoral immune responses induced by the 1x10
11
 vp dose (for the 445 
monovalent form) are higher than those induced by the lower doses, reason why the 1x10
11
 vp 446 
dose was selected for Phase II and Phase III studies (NCT02485301 on ClinicalTrials.gov). In 447 
conclusion, ChAd3-EBO-Z was safe, more reactogenic than routine vaccinations but with 448 
only self-limited, usually mild, AEs considering the severity of the disease. This acceptable 449 
safety profile linked to Ebola specific antibody response and polyfunctional CD8+ specific T 450 
cell response provides a reliable basis for proceeding with efficacy trials in Africa.  451 
 452 
Research in context 453 
Evidence before this study 454 
Clinical trial reports were searched for in PubMed up to Aug 17, 2015 using the terms 455 
“Ebola” AND “vaccine” with no language or date restriction. Two DNA vaccines and one 456 
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recombinant adenovirus serotype 5 (rAd5) using different versions of the Ebola or Marburg 457 
GP protein had been tested in the last ten years. Chimpanzee Adenovirus 3 (ChAd3) vectored 458 
vaccines using monovalent and bivalent formulations of the Ebola virus glycoprotein (GP) 459 
were tested in late 2014 in Phase I clinical trials in the US and UK with limited sample size. A 460 
recombinant Vesicular Stomatitis Virus (rVSV) vectored Ebola vaccine was simultaneously 461 
tested in a multisite phase I trial. More recently, a report of a Phase I conducted in China 462 
using an rAd5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic 463 
strain was published. No safety issues arose from all these trials besides cases of arthritis and 464 
rash with rVSV predominantly seen at one site. All these trials conducted simultaneously to 465 
ours were published as preliminary reports including safety and immunogenicity data up to 466 
day 28 post-injection.  467 
 468 
Added value of this study 469 
The present paper provides the most comprehensive results of a phase I/II trial with ChAd3 470 
vector-based vaccine expressing the Ebola GP. This trial was the only one that was placebo-471 
controlled, which allows the most accurate assessment of safety and reactogenicity. Among all 472 
Ebola vaccine trials, this is the only one that provides safety and immunogenicity results up to 473 
6 months post-injection, the latter providing some insight on the value of the vaccine over the 474 
course of an epidemic. In our trial, no safety signal was observed. All vaccinees showed 475 
humoral responses that peaked at day 28, and then decreased by about half at month 6 post-476 
injection. IFN-γ mononuclear cell responses were still present at that time too. 477 
 478 
Implications of all the available evidence 479 
Comparing results of the present report with those of the rVSV vectored Ebola vaccine at 480 
2x10
7
 or 5x10
7
 pfu, we can conclude that the safety profile of the ChAd3-EBO-Z at 10
10 
doses 481 
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is slightly better, but the humoral responses slightly lower at 1 month post-injection. 482 
Considering the good safety profile of ChAd3-EBO-Z at 10
10
 doses in the present trial, it 483 
seems appropriate to use the 1x10
11
 dose to proceed to Phase II and III trial in Africa as 484 
planned, especially so because the few available safety data with ChAd3-EBO-Z at 1x10
11
 485 
show acceptable adverse events (AEs) profile and, more importantly, similar antibody 486 
responses as those obtained with the 2x10
7
 pfu dose of the rVSV vectored vaccine. Assuming 487 
that the anti-GP antibody concentration is correlated with protection (even if not protective 488 
themselves), we can thus hope that the promising efficacy results observed in the preliminary 489 
report of the rVSV vectored vaccine in the Phase III in Guinea could also be obtained using 490 
the ChAd3-EBO-Z vaccine at a 1x10
11
 dose.  The persistence of antibodies at month 6, 491 
although at lower concentration, may indicate that some protection remains. This needs to be 492 
confirmed though in a thorough Phase III trial. Detailed correlation of immunological data 493 
and protection in non-human primates studies may also give some insight on efficacy, if a 494 
Phase III trial becomes impossible to conduct because of insufficient number of new Ebola 495 
virus disease cases. 496 
 497 
 498 
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Table 1: Characteristics of subjects at baseline 
 
 
 
 
 
Placebo 2.5 x 10
10
 vp 5 x 10
10
 vp 2.5 x 10
10
 vp 5 x 10
10
 vp
N 20 42 40 9 9
Male 11 (55%) 22 (52%) 19 (48%) 4 (44%) 3 (33%)
Female 9 (45%) 20 (48%) 21 (52%) 5 (56%) 6 (67%)
White 16 (80%) 40 (95%) 35 (88%) 9 (100%) 6 (67%) 
Black 1 (5%) 1 (2%) 1 (2%) 0 2 (22%)
Hispanic 0 0 1 (2%) 0 0
Other 3 (15%) 1 (2%) 3 (8%) 0 1 (11%)
Mean(SD) 37.2 (13.4) 30.7 (11.1) 33.2 (13.1) 42 (12.4) 46 (10.8)
Median[min,max] 37 [19-61] 27.5 [19-63] 27 [19-63] 39 [28-62] 43 [32-64]
Mean(SD) 23.5 (3.6) 23.7 (3.3) 24.2 (2.9) 23.4 (4.1) 26.6 (3.9)
Median[min,max] 22.3 [18.9-33.9] 23.3 [17.6-32] 23.8 [19.4-31.2] 23.4 [18.3-30.3] 27.4 [20.3-33.2]
Age (years)
BMI (kg/m2)
Non-deployed Potentially deployed  
Gender
Ethnicity
28 
 
Table 2: Frequency and maximum intensity of solicited local and systemic AEs (occurring up to D7 +/- 1) and of unsolicited related AEs 
(up to D28) per arm.  
 
* erythema at injection site of  11 cm of diameter, at D9 post injection. (P-value obtained using Fisher’s 
exact test). 
Pain Grade 1 5 (25%) 32 (76%) 25 (62%) 6 (67%) 7 (78%)
Grade 2 0 (0%) 1 (2%) 5 (12%) 1 (11%) 0 (0%)
TOTAL 5 (25%) 33 (79%) 30 (75%) <0.01 0.8 7 (78%) 7 (78%)
Swelling Grade 1 0 (0%) 0 (0%) 2 (5%) 0 (0%) 0 (0%)
Grade 2 0 (0%) 0 (0%) 1 (2%) 0 (0%) 0 (0%)
TOTAL 0 (0%) 0 (0%) 3 (8%) 1 0.11 0 (0%) 0 (0%)
Erythema Grade 1 0 (0%) 2 (5%) 2 (5%) 1 (11%) 0 (0%)
TOTAL 0 (0%) 2 (5%) 2 (5%) 0.58 1 1 (11%) 0 (0%)
Grade 1 0 (0%) 0 (0%) 4 (10%) 0 (0%) 0 (0%)
TOTAL 0 (0%) 0 (0%) 4 (10%) 0.58 0.05 0 (0%) 0 (0%)
Fatigue/Malaise Grade 1 6 (30%) 24 (57%) 22 (55%) 4 (44%) 4 (44%)
Grade 2 0 (0%) 3 (7%) 4 (10%) 1 (11%) 1 (11%)
TOTAL 6 (30%) 27 (64%) 26 (65%) 0.01 1 5 (56%) 5 (56%)
Musculo-articular painGrade 1 5 (25%) 17 (40%) 17 (42%) 3 (33%) 2 (22%)
Grade 2 0 (0%) 1 (2%) 6 (15%) 0 (0%) 1 (11%)
TOTAL 5 (25%) 18 (43%) 23 (57%) 0.05 0.27 3 (33%) 3 (33%)
Chills Grade 1 0 (0%) 6 (14%) 9 (22%) 3 (33%) 3 (33%)
Grade 2 0 (0%) 3 (7%) 2 (5%) 0 (0%) 0 (0%)
TOTAL 0 (0%) 9 (21%) 11 (28%) 0.01 0.61 3 (33%) 3 (33%)
Nausea Grade 1 4 (20%) 5 (12%) 3 (8%) 2 (22%) 1 (11%)
Grade 2 0 (0%) 0 (0%) 1 (2%) 0 (0%) 0 (0%)
TOTAL 4 (20%) 5 (12%) 4 (10%) 0.28 1 2 (22%) 1 (11%)
Fever Grade 1 0 (0%) 6 (14%) 7 (18%) 2 (22%) 1 (11%)
Grade 2 1 (5%) 5 (12%) 5 (12%) 0 (0%) 1 (11%)
Grade 3 0 (0%) 1 (2%) 1 (2%) 0 (0%) 0 (0%)
TOTAL 1 (5%) 12 (29%) 13 (32%) 0.02 0.81 2 (22%) 2 (22%)
Headache Grade 1 4 (20%) 18 (43%) 15 (38%) 1 (11%) 4 (44%)
Grade 2 2 (10%) 10 (24%) 10 (25%) 2 (22%) 2 (22%)
Grade 3 0 (0%) 1 (2%) 1 (2%) 0 (0%) 0 (0%)
TOTAL 6 (30%) 29 (69%) 26 (65%) <0.01 0.82 3 (33%) 6 (67%)
Abdominal pain Grade 1 0 (0%) 1 (2%) 1 (2%) 0 (0%) 1 (11%)
TOTAL 0 (0%) 1 (2%) 1 (2%) 1 1 0 (0%) 1 (11%)
Conjunctivitis Grade 1 0 (0%) 0 (0%) 1 (2%) 1 (11%) 0 (0%)
TOTAL 0 (0%) 0 (0%) 1 (2%) 1 0.49 1 (11%) 0 (0%)
Rhinitis Grade 1 0 (0%) 1 (2%) 0 (0%) 0 (0%) 1 (11%)
TOTAL 0 (0%) 1 (2%) 0 (0%) 1 1 0 (0%) 1 (11%)
Sweating Grade 1 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Grade 2 0 (0%) 1 (2%) 0 (0%) 0 (0%) 0 (0%)
TOTAL 0 (0%) 1 (2%) 0 (0%) 1 1 0 (0%) 0 (0%)
Others Grade 1 0 (0%) 1 (2%) 1 (2%) 0 (0%) 0 (0%)
Grade 2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Grade 3 0 (0%) 0 (0%) 1 (2%)* 0 (0%) 0 (0%)
TOTAL 0 (0%) 1 (2%) 2 (5%) 1 0.61 0 (0%) 0 (0%)
SY
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Placebo vs 
Vaccinated 
(N=20 vs 
N=82)
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N=40)
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Figures legends 
 
Figure 1: Study flow diagram.  
 
Figure 2: Proportion of volunteers affected and severity of AEs, up to D28, per arm (placebo, dose 2.5x10
10
 
vp, dose 5.0x10
10
 vp) among non-deployed volunteers 
 
Figure 3: Anti-EBOZ-Glycoprotein IgG responses in the different arms. The kinetics of responses as 
assessed by a commercial ELISA (ADI) are shown in Panel A, where results in boxplots indicate median 
and quartiles with the 95% Confidence Interval of IgG concentrations (µg/ml) per arm and.where geometric 
mean concentrations  (GMC) (µg/ml) are compared between arms (Mann Whitney; **** p<0.0001.). Panel 
B shows individual VRC endpoint EC90 titers at D28. In red the GMC and the 95%CI. Black dots show 
volunteers who seroconverted. Panel C shows Spearman’s correlation between the two ELISA assays 
(Lausanne and VRC), placebo arm are in white, 2.5x10
10
 vp arm in light grey and 5x10
10
 vp arm in dark 
grey. 
 
Figure 4: EBOZ GP-specific memory T cells responses. Panel A shows the kinetics of individual CD4+  and 
CD8+ responses expressed as frequencies of subsets expressing at least one cytokine, IFN-γ, IL-2 or TNF-α. 
Results are shown as boxplots with median, quartiles and 5% centiles, for each arm, placebo in white 
(n=20), dose 2.5x10
10
 vp in light grey (n=51) and dose 5x10
10
 in dark grey (n=49). Kruskal-Wallis test was 
used to assess statistical significance with placebo arm. Panels B and C show the proportions of GP-specific 
memory CD4 and CD8 T cells that produce any combination of the 3 cytokines, at D14 and D28, in the arms 
of vaccinees.  
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Methods supplemental text 75 
Inclusion and exclusion criteria 76 
The volunteers had to meet all following inclusion and exclusion criteria to be eligible for the 77 
study. 78 
Inclusion criteria 79 
1. Healthy adults aged 18 to 65 years 80 
2. Able and willing (in the investigator’s opinion) to comply with all study requirements 81 
3. Willing to allow the investigators to discuss the volunteer’s medical history with their general 82 
practitioner 83 
4. For females of reproductive capacity and male, having practiced continuous effective 84 
contraception for 21 days prior to enrolment (see section 6.3.3), and willing to practice 85 
continuous effective contraception for 6 months post vaccination 86 
5. For females of reproductive capacity, having a negative pregnancy test on the day(s) of 87 
screening and vaccination if >7 days interval 88 
6. Agreement to refrain from blood donation during the course of the study 89 
7. Provide written informed consent 90 
Exclusion criteria 91 
1. Participation in another research study involving receipt of an investigational product in the 30 92 
days preceding enrolment, or planned use during the study period 93 
2. Prior receipt of an investigational Ebola or Marburg vaccine or a chimpanzee adenovirus 94 
vectored vaccine 95 
3. Receipt of any live, attenuated vaccine within 28 days prior to enrolment 96 
4. Receipt of any subunit or killed vaccine within 14 days prior to enrolment (influenza vaccination 97 
was encouraged prior to participation) 98 
5. Receipt of any investigational vaccine within 3 months prior to enrollment 99 
6. Administration of immunoglobulins and/or any blood products within the three months 100 
preceding the planned administration of the vaccine candidate 101 
7. Any confirmed or suspected immunosuppressed or immunodeficient state, including HIV 102 
infection; asplenia; recurrent, severe infections and chronic (more than 14 days) 103 
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immunosuppressive medication within the past 6 months (inhaled and topical steroids were 104 
allowed) 105 
8. History of allergic reactions likely to be exacerbated by any component of the vaccine, 106 
9. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema. 107 
10. Any history of anaphylaxis in reaction to vaccination 108 
11. Pregnancy, lactation or willingness/intention to become pregnant during the study 109 
12. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ) 110 
13. History of serious psychiatric condition 111 
14. Poorly controlled asthma or thyroid disease 112 
15. Seizure in the past 3 years or treatment for seizure disorder in the past 3 years 113 
16. Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior history of 114 
significant bleeding or bruising following IM injections or venepuncture 115 
17. Any other serious chronic illness requiring hospital specialist supervision 116 
18. Current anti-tuberculosis prophylaxis or therapy 117 
19. Suspected or known current alcohol abuse (> 14 units/week for women and >21 units/week for 118 
men) 119 
20. Suspected or known injecting drug abuse in the 5 years preceding enrolment 120 
21. Seropositive for hepatitis B surface antigen (HBsAg) 121 
22. Seropositive for hepatitis C virus (antibodies to HCV) 122 
23. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests 123 
or urinalysis  124 
24. Any other significant disease, disorder or finding which may significantly increase the risk to the 125 
volunteer because of participation in the study, affect the ability of the volunteer to participate 126 
in the study or impair interpretation of the study data 127 
 128 
  129 
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Unblinding 130 
Due to the urgency of having results to select the optimal dose for Phase IIb and III to be 131 
conducted in Africa from January 2015, the study was unblinded 14 days after the vaccination 132 
of the last subject only for the study statistician (investigators and volunteers remained blinded 133 
until the end of the study). Tables of results provided by the statistician with no identity or 134 
study code (to keep the blinding) allowed investigators and sponsor to best assess safety and 135 
immunogenicity results of all ongoing and completed Phase I studies in order to select the most 136 
appropriate vaccine dose for further trials in Africa. 137 
Vaccine 138 
The pre-ChAd3 vector is derived from the WT ChAd3 genome isolated from a healthy young 139 
chimpanzee housed at New Iberia Research Center facility (New Iberia Research Center; The 140 
University of Louisiana at Lafayette). The viral genome was cloned into a plasmid DNA vector 141 
and subsequently modified to delete the E1 and E4 region of the viral genome. 142 
The drug substance was manufactured under Good Manufacturing Practice (GMP) conditions 143 
by ADVENT S.r.l. (Rome, Italy, under contract to GlaxoSmithKline (GSK) and the NIH) and the 144 
vaccine and diluent were manufactured by the VRC Vaccine Pilot Plant (VPP), operated by the 145 
Vaccine Clinical Materials Program, Leidos Biomedical Research, Inc., Frederick, MD. ChAd3-146 
EBO-Z was supplied as a sterile, aqueous, buffered solution filled into single dose vials at a final 147 
concentration of 9.1 x 1010 vp per ml (after final release). Fill volume was 0.7 ml per vial. The 148 
diluent was comprised of formulation buffer and was used to dilute ChAd3-EBOZ to the correct 149 
dosage for IM administration. The formulation buffer, pH 7.4, was composed of 10 mM Tris, 10 150 
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mM Histidine, 5% Sucrose (w/v), 75 mM Sodium Chloride, 1 mM Magnesium Chloride, 0.02% 151 
Polysorbate 80 (PS-80) (w/v), 0.1 mM EDTA, and 0.5% Ethanol (v/v).  152 
Procedures 153 
All AEs, either solicited or unsolicited, were transferred in the source documents and entered in 154 
an electronic CRF by the investigator. 155 
Grading 156 
Severity grading criteria for local and systemic AEs : 157 
Grade 0   None 158 
Grade 1   Mild: Transient or mild discomfort (< 48 hours); no medical intervention/therapy required 159 
Grade 2   Moderate: Mild to moderate limitation in activity – some assistance may be needed; no or 160 
minimal medical intervention/therapy required 161 
Grade 3   Severe: Marked limitation in activity, some assistance usually required; medical 162 
intervention/therapy required, hospitalisation possible 163 
Severity grading for fever : 164 
Grade 1   37.6°C-38.0°C  165 
Grade 2   38.1°C-39.0°C 166 
Grade 3   >39.0°C 167 
  168 
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Severity grading criteria for local adverse events:  169 
Pain at injection site  170 
Grade 1   Pain that is easily tolerated 171 
Grade 2   Pain that interferes with daily activity 172 
Grade 3   Pain that prevents daily activity 173 
Erythema at injection site diameter 174 
Grade 1   >3 - ≤50 mm 175 
Grade 2   >50 - ≤100 mm 176 
Grade 3   >100 mm 177 
Swelling at injection site diameter 178 
Grade 1   >1 - ≤20 mm 179 
Grade 2   >20 - ≤50 mm 180 
Grade 3   >50 mm 181 
 182 
Causality assessment 183 
For every unsolicited AE, an assessment of the relationship of the event to the administration of 184 
the vaccine was undertaken. An intervention-related AE referred to an AE for which there was a 185 
possible, probable or definite relationship to administration of the vaccine. An interpretation of 186 
the causal relationship of the intervention to the AE in question was made, based on the type of 187 
event, the relationship of the event to the time of vaccine administration, and the known 188 
biology of the vaccine therapy. 189 
No Relationship  190 
No temporal relationship to study product and 191 
Alternate aetiology (clinical state, environmental or other interventions); and 192 
Does not follow known pattern of response to study product 193 
Unlikely  194 
Unlikely temporal relationship to study product and 195 
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Alternate aetiology likely (clinical state, environmental or other interventions) and 196 
Does not follow known typical or plausible pattern of response to study product. 197 
Possible  198 
Reasonable temporal relationship to study product; or 199 
Event not readily produced by clinical state, environmental or other interventions; or 200 
Similar pattern of response to that seen with other vaccines 201 
Probable  202 
Reasonable temporal relationship to study product; and 203 
Event not readily produced by clinical state, environment, or other interventions or 204 
Known pattern of response seen with other vaccines 205 
Definite  206 
Reasonable temporal relationship to study product; and 207 
Event not readily produced by clinical state, environment, or other interventions; and 208 
Known pattern of response seen with other vaccines 209 
Antibody response 210 
Anti-EBOZ GP IgG responses were assessed by ELISA using a commercial kit (AE 320620-1, Alpha 211 
Diagnostics International, Texas, USA) according to the manufacturer’s instructions with sera diluted at 212 
1:200 in duplicates. For each volunteer, sera taken at various time-points were evaluated on the same 213 
plate. Optical density (OD) was read at 450nm with 630nm substraction on a microplate reader (Opsys 214 
MR, Dynex Technologies) and mean OD converted to µg/ml using the standard curve of the kit 215 
calibrator. Samples giving a signal above the upper limit of the curve were evaluated at a higher dilution.  216 
In parallel, the sera at D0 and D28 were tested for humoral responses by the Vaccine Research Center 217 
(VRC) using the methodology previously described4 for comparison with all phase I trial results.  218 
 219 
Cell mediated immunity 220 
Enzyme–linked immunospot (ELISPOT) were performed at all time-points with the use of overlapping 221 
peptide pools. Peripheral blood mononuclear cells (PBMC) from blood taken at D0 (pre vaccination), and 222 
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D7, D14, D28 and D180 post-injection were separated on a density gradient using Vacutainer CPT 223 
(Becton, Dickinson and Company), washed and stored in liquid nitrogen until analysis.  224 
Vaccine-induced T-cell responses were evaluated by means of a qualified intracellular cytokine staining 225 
assay performed by the VRC and described elsewhere(1,2). Cryopreserved PBMC obtained at D0, D14, 226 
and D28 were stimulated with overlapping peptide pools matching the vaccine insert for glycoprotein 227 
Zaire and were quantified to determine the proportion of CD4 and CD8 T cells producing interleukin-2 228 
(IL-2), interferon-γ (IFN-γ), or tumor necrosis factor alpha (TNF-α) Antibodies are from BD Biosciences 229 
unless otherwise stated: Anti-CD28-Cy5PE, Anti-CD45RA-Cy7PE, Anti-CCR7-Ax680 (ReaMetrix), 230 
Anti-IFN-γ-APC, Anti-IL-2-PE, Anti-TNF-α-FITC, Anti-CD4-ECD (Beckman Coulter), Anti-CD3-231 
Cy7APC, Anti-CD8-Pacific Blue, and Aqua-Blue.  Cells are stained with Aqua Blue at room temperature 232 
for 20 minutes, followed immediately by staining with the surface markers (CD3, CD28, CD45RA, 233 
CCR7) for an additional 20 minutes.  Cells are washed twice, permeabilized with 100 µL/well CytoFix-234 
CytoPerm reagent (BD) with twenty minute incubation at 2-8
o
C minutes, then washed twice with 235 
PermWash (BD).  Intracellular staining (CD4, CD8, IFN- γ, IL-2, TNF-α ) is in a total of 100 µL/well at 236 
room temperature for 20 minutes, followed by 3 washes with PermWash.  The cells are resuspended in 237 
1% paraformaldehyde and stored at 4°C for no longer than 36 hours prior to flow cytometry analysis.  238 
Multi-parameter flow cytometric analysis is performed on a LSR-II flow cytometer (BDIS).  Between 239 
50,000 and 250,000 events are acquired.  Results are analyzed using FlowJo software (Tree Star 240 
Software; Ashland, OR).  The same gating strategy is used for all clinical testing (Figure 6S) .A response 241 
with a percentage of positive cells stimulated minus unstimulated above 0.05% or 0.08% for CD8 IFN-γ 242 
and CD8 TNF-α, was considered positive. A responder had a positive CD4 or CD8 response for at least 243 
one cytokine to at least one peptide pool at any time points. In addition, memory T cells were identified 244 
on the basis of markers expression and their cytokine production quantified using Boolean gating. 245 
 246 
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IFN- ELISPOT 247 
 248 
The frequency of IFN- secreting cells per million in response to GP EBOZ was assessed by 249 
ELISPOT (Beckton Dickinson). After thawing, 250 000 PBMC per well were stimulated 20h in 250 
triplicates with 6 pools of 20-22 peptides covering the sequence of the GP EBOZ protein minus 251 
the last C-terminal 16 amino acids or with phytohemagglutinin (PHA) or unstimulated 252 
(dimethylsulfoxyde, DMSO alone) as positive and negative controls, respectively. The peptides 253 
were 15-mers overlapping by 10 amino acids at a final concentration of 2.5 g/ml of each 254 
peptide. To detect cytokines as discrete spots, a second anti-IFNantibody biotinylated, 255 
streptavidin-enzyme and an insoluble substrate were used. Results in spot forming units (SFU) 256 
per million PBMC were given with the help of computer assisted video image analyzer (EliSpot 257 
Robotic Systems with AID EliSpot Software Version 6.x (ELROBO6i, AID, D-Straßberg)), averaged 258 
across triplicates, and values in unstimulated wells were substracted. Negative values were set 259 
to zero and finally, the response to GP EBOZ calculated as the sum of the responses to the 6 260 
pools of peptides. An ELISPOT was validated if the response to the negative control was less 261 
than 50 SFU / million PBMC and the positive control above 500 SFU / million PBMC. 262 
ChAd3 and Ad5 Serologic Assessment 263 
 264 
An adenovirus serum neutralization assay was performed to assess neutralizing antibody titers 265 
in order to determine baseline and vaccine induced (week 4) neutralization of ChAd3 and 266 
human Ad5. Reciprocal antibody titers are reported as the inhibitory concentration 90% (IC90; 267 
the titer at which 90% of infectivity is inhibited). The assay was performed according to 268 
previous description(3). 269 
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Data analysis 270 
To compare the antibody titers IgG obtained in the present study with those obtained in the 271 
Ebola challenge studies in macaques(4,5), we used the titers measured at the VRC. 272 
To investigate the effect of demographic characteristics on peak antibody concentration at D28 273 
or maintenance at D180, a regression model was used including age, gender, BMI. The same 274 
was done to investigate the relation of safety data with immunological response, by studying 275 
the impact of grade 2 and 3 AEs, fever, fatigue, adenopathy and headache on antibody 276 
response. 277 
  278 
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Supplemental tables and figure 279 
 280 
Figure 1S: Subjects with fever (>37.5°C axillary temperature) per arm. 281 
*Fever at day 4 associated to a streptococcal angina. 282 
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P-value were calculated with Mann-Whitney test.  
Table 1S: Mean changes in haematology values from baseline to D1, D7, D14 and D28 with 95%CI per arm.
N Mean 95% CI N Mean 95% CI N Mean 95% CI
Placebo vs 
Vaccinated
Low vs 
High Dose
D1 9 1.9  -4.6-8.4 25 1.3  -8.5-11.1 27 -1.5  -11.3-8.3 0.32 0.03
D7 9 -1  -10.8-8.8 25 -1.7  -9.7-6.3 27 -4.1  -16.8-8.6 0.31 0.17
D14 9 -5  -14-4 24 -2.6  -12.4-7.2 27 -7.3  -19.3-4.7 0.97 <0.001
D28 9 -1.9  -9.5-5.7 25 -2  -13-9 27 -4.4  -16.9-8.1 0.54 0.26
D1 11 0.5  -8.9-9.9 26 2.5  -5.7-10.7 21 0.5  -9.5-10.5 0.67 0.24
D7 11 -1.1  -12.3-10.1 26 -4.1  -14.3-6.1 22 -2.7  -15-9.6 0.27 0.29
D14 11 -7.1  -19.6-5.4 26 -5.4  -18.3-7.5 22 -4  -16.9-8.9 0.24 0.3
D28 11 -6.2  -18.2-5.8 26 -3.8  -20.5-12.9 21 -4.2  -15.8-7.4 0.31 0.91
D1 20 0.1  -1.9-2.1 51 0  -2.4-2.4 48 -0.3  -3-2.4 0.49 0.67
D7 20 -0.1  -3.2-3 51 0.2  -2.3-2.7 49 -0.2  -2.4-2 0.65 0.09
D14 20 -0.1  -3.2-3 50 0  -2.5-2.5 49 0.1  -2.4-2.6 0.99 0.67
D28 20 0.2  -2.2-2.6 51 -0.1  -2.5-2.3 48 -0.3  -2.7-2.1 0.24 0.75
D1 20 0.4  -7.2-8 51 -10.3  -24.2-3.6 48 -8.9  -23.8-6 <0.001 0.32
D7 20 -0.5  -16.2-15.2 51 -0.5  -14.8-13.8 49 0.8  -13.3-14.9 0.77 0.54
D14 20 -1.8  -14.9-11.3 50 0.9  -11.1-12.9 49 -0.9  -15.8-14 0.3 0.12
D28 20 -1.5  -11.9-8.9 51 0.6  -12.1-13.3 48 0.9  -9.9-11.7 0.07 1
D1 20 -0.8  -11.8-10.2 51 8.3  -9.7-26.3 48 6.4  -12-24.8 <0.001 0.3
D7 20 0.2  -18-18.4 51 1.1  -14.4-16.6 49 -0.7  -16.6-15.2 0.89 0.3
D14 20 1.3  -14.4-17 50 -1.6  -15.1-11.9 49 0.6  -15.1-16.3 0.33 0.21
D28 20 1.3  -10.1-12.7 51 -0.6  -15.1-13.9 48 -1.3  -13.8-11.2 0.11 0.57
D1 20 4.5  -29-38 51 -20.6  -60.4-19.2 47 -18.8  -53.7-16.1 <0.001 0.72
D7 20 -5  -48.5-38.5 51 7  -45.1-59.1 48 3.8  -38.7-46.3 0.11 0.33
D14 20 3.3  -43.9-50.5 50 9.6  -45.1-64.3 48 8.4  -46.9-63.7 0.35 0.93
D28 20 15.8  -25.9-57.5 51 4.6  -47.1-56.3 47 -0.1  -48.5-48.3 0.02 0.7
D1 20 0.4  -3.1-3.9 51 0  -2.5-2.5 47 0.6  -2.5-3.7 0.79 0.1
D7 20 -0.2  -4.1-3.7 50 0.1  -2.4-2.6 48 0.4  -2-2.8 0.45 0.29
D14 20 0.2  -3.3-3.7 50 -0.1  -3-2.8 48 0.4  -4.1-4.9 0.43 0.56
D28 20 0.2  -3.3-3.7 50 -0.3  -3.8-3.2 47 0.1  -4.4-4.6 0.24 0.76
Lymphocytes (G/l)
Neutrophil (G/l)
Platelets (G/l)
aPTT (seconds)
P-valuePlacebo 2.5 x 1010 vp 5 x 1010 vp
Hb - Men (g/l)
Hb - Women (g/l)
Total white cells (G/l)
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P-value were calculated with Mann-Whitney test 3 
 4 
Table 2S: Mean changes in biochemistry values from baseline to D1, D7, D14 and D28 with 95%CI per arm. 5 
 6 
 7 
N Mean 95% CI N Mean 95% CI N Mean 95% CI
Placebo vs 
Vaccinated
Low vs High 
Dose
 D1 20 0  -15.3-15.3 51 4.2  -8.5-16.9 49 1.9  -12.2-16 0.1 0.23
 D7 20 -1.7  -17.8-14.4 51 0.1  -10.9-11.1 49 -2.5  -21.5-16.5 0.63 0.26
 D14 20 -1.6  -18.3-15.1 50 1.3  -15.8-18.4 48 -2.6  -20.2-15 0.64 0.03
 D28 20 -1.7  -15.4-12 51 2.6  -11.1-16.3 48 -1.8  -19.6-16 0.18 0.01
 D1 2 3  -8.2-14.2 17 2.4  -4.3-9.1 18 4.1  -8.4-16.6 0.81 0.81
 D7 2 -3.5  -7.6-0.6 11 -2.6  -16.1-10.9 14 1.1  -4-6.2 0.07 0.04
 D14 2 -4  -12.2-4.2 12 -2.2  -16.5-12.1 13 1.8  -10.5-14.1 0.1 0.24
 D28 2 2  2-2 10 -2.4  -18.1-13.3 12 0.3  -3.4-4 0.13 0.3
 D1 20 -0.4  -8.8-8 50 0.5  -6.8-7.8 49 0.7  -6.6-8 0.16 0.69
 D7 20 -0.9  -13.2-11.4 49 -0.1  -11.1-10.9 49 3  -15.8-21.8 0.65 0.38
 D14 20 0.1  -13.6-13.8 49 0.1  -12.8-13 49 1  -8.4-10.4 0.82 0.59
 D28 20 -1.4  -16.3-13.5 50 -0.3  -14.6-14 48 1.8  -14.5-18.1 0.39 0.68
 D1 20 0.8  -11.5-13.1 50 0.4  -7-7.8 49 0  -7.3-7.3 0.59 0.7
 D7 20 0.1  -3.8-4 50 -0.1  -11.1-10.9 49 1.9  -18.9-22.7 0.63 0.07
 D14 20 1.2  -6.1-8.5 49 -0.5  -11.3-10.3 49 1.1  -11.4-13.6 0.38 <0.0001
 D28 20 -0.8  -17.3-15.7 50 -0.7  -13-11.6 48 1.1  -34.8-37 0.44 0.57
 D1 20 0.6  -3.7-4.9 50 0.6  -3.3-4.5 49 0.5  -5-6 0.98 0.25
 D7 20 0.2  -5.5-5.9 50 -0.1  -10.1-9.9 49 1.1  -8.7-10.9 0.49 0.63
 D14 20 -0.9  -8.7-6.9 49 -0.7  -15.8-14.4 49 -0.5  -11.9-10.9 0.93 0.72
 D28 20 0.2  -8.6-9 50 -0.6  -12.6-11.4 48 0.8  -21.2-22.8 0.42 0.86
 D1 19 1.5  -5.9-8.9 48 1.1  -3.6-5.8 47 0.9  -6.5-8.3 0.35 0.4
 D7 18 1.1  -4-6.2 49 -0.9  -7.2-5.4 48 -1.7  -14.2-10.8 0.01 0.7
 D14 19 -0.2  -8-7.6 48 -0.7  -7.2-5.8 47 -1.4  -9.8-7 0.43 0.26
 D28 18 0.6  -8.4-9.6 49 -1.1  -7.4-5.2 47 -1.3  -13.8-11.2 0.18 0.75
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Figure 2S: Frequency of individuals with worsening hematology lab values between D0 and D28 9 
according to vaccine doses. 10 
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Figure 3S: EBOZ GP specific IFN-γ responses.  12 
The kinetics of individual IFN-  peptides was assessed by ELISPOT. Results are 13 
shown as boxplots with median, quartiles and 5% centiles, for each group, placebo in white (n=20), dose 14 
2.5x1010 vp in light grey (n=51) and dose 5 x1010 vp in dark grey (n=49). Kruskal-Wallis test was used to 15 
assess statistical significance with placebo group. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 16 
Friedman test was used to assess statistical significance within groups between D0 and D180: for the two 17 
vaccines doses, D180 value was higher than D0 value (p=0.001). 18 
18 
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Figure 4S: EBOZ GP specific T cells responses.  21 
The kinetics of individual CD4+ (left Panels) and CD8+ (right Panels) responses are expressed as 22 
frequencies of subsets expressing IFN-γ (Panels A), IL-2 (Panels B) or TNF-23 
are shown as boxplots with median, quartiles and 5% centiles, for each group, placebo in white (n=20), 24 
dose 2.5x1010 vp in light grey (n=51) and dose 5.0x1010 vp in dark grey (n=49). Kruskal-Wallis test was 25 
used to assess statistical significance with placebo group. *, p<0.05; **, p<0.01; ***, p<0.001; ****, 26 
p<0.0001. 27 
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 30 
 31 
Study Group n/N % (95% CI) 
Comparisons 
with Saline                      
b
 
Comparisons 
with cAd3-EBOZ 
2.5x10
10
 
b
 
Saline 
Week 4 (Day 28) 1/20 5.0 0.1 - 24.9 - - 
By Week 4
c
 1/20 5.0 0.1 - 24.9 - - 
cAd3-EBOZ 2.5x10
10
 
Week 4 (Day 28) 49/51 96.1 86.5 - 99.5 pf<0.001 - 
By Week 4
c
 49/51 96.1 86.5 - 99.5 pf<0.001 - 
cAd3-EBOZ 5.0x10
10
 
Week 4 (Day 28) 46/48 95.8 85.7 - 99.5 pf<0.001 pf=1 
By Week 4
c
 46/48 95.8 85.7 - 99.5 pf<0.001 pf=1 
Table 3S:  Summary of VRC ELISA positive response rate for the Ebola Mayinga Strain by 32 
vaccination dose 33 
n = number of subjects with positive response; N = number of subjects evaluated; CI = Confidence 34 
Interval (Clopper-Pearson). 35 
a. Positive ELISA response was defined as a statistically significant increase in titre from baseline. 36 
b. Pairwise comparisons between groups were evaluated using Fisher’s exact test (pf). 37 
c. Subjects were counted as having a positive response by Week 4 if they had a positive response at 38 
Week 2 or Week 4. 39 
  40 
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 41 
  GMC at D28 GMC at D180 
  coefficient std error p-value coefficient std error p-value 
              
Age -0.01 0.00 0.12 0.00 0.00 0.76 
Gender -0.03 0.08 0.71 0.02 0.07 0.78 
BMI 0.01 0.01 0.45 -0.01 0.01 0.18 
              
Grade 2 and 3 AEs 0.08 0.08 0.27 0.02 0.07 0.77 
Fever -0.20 0.08 0.02 -0.15 0.07 0.05 
Fatigue -0.02 0.08 0.85 -0.08 0.07 0.27 
Adenopathy -0.09 0.25 0.72 -0.01 0.23 0.98 
Headache -0.15 0.13 0.24 -0.08 0.11 0.47 
              
Table 4S: Determinant analysis (ANCOVA) of GMC at D28 and persistence at D180.  42 
Analyzed data is a subset of the full dataset with only individuals who received the vaccine (those who 43 
received placebo were omitted in the analysis). An analysis of covariance was performed here (including 44 
simultaneously continuous and categorical/binary variables). The outcomes were titres at D28 and D180 45 
(analyzed independently on a log10 scale). 46 
Variables  description: 47 
Age continuous outcome             
Gender binary outcome             
BMI continuous outcome             
Grade 2 and 3 AEs binary outcome TRUE if person has experienced at least 1 AE with grade ≥2   
Fever binary outcome TRUE if person has experienced at least 1 fever      
Fatigue binary outcome TRUE if person has experienced a fatigue at D1     
Adenopathy binary outcome TRUE if person has experienced an axillary node enlargement  at D1 
Headache binary outcome TRUE if person has experienced a headache at D1 with grade ≥2   
                
 48 
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 Figure 5S: Anti-ChAd3 neutralizing antibodies. Panel A show antibody titers pre and 4 weeks post 63 
vaccination in volunteers from the 3 arms. Panels B and C show the correlation between anti-ChAd3 64 
antibodies at D0 and EBOZ GP specific responses obtained at D28 in all vaccinees, humoral responses in 65 
Panel B and IFN-ƴ CD8+ responses in Panel C. Spearman r and p values are indicated. 66 
 67 
  68 
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 69 
 70 
Figure 6S:  Gating hierarchy to enumerate antigen-specific T cells. 71 
Stimulated cells were stained as described and analyzed by flow cytometry.  For each run, identical gates 72 
were applied to all samples; for the study, all fluorescence gates were identical.  The sample was 73 
progressively gated to identify single cells, live CD3+ T cells, and CD4 or CD8 T cells as shown in the top 74 
row.  Within these lineages, memory T cells were identified by excluding CD45RA+CCR7+ naïve T cells 75 
(second row).  Within memory T cells, individual gates for each cytokine were used (bottom). 76 
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